

Accepted Manuscript

Title: Design, synthesis and bioactivity of chalcones and its analogues

Authors: Chao Niu, Adila Tuerxuntayi, Gen Li, Madina Kabas, Chang-Zhi Dong, Haji Akber Aisa



PII: S1001-8417(17)30096-7
DOI: <http://dx.doi.org/doi:10.1016/j.cclet.2017.03.018>
Reference: CCLET 4013

To appear in: *Chinese Chemical Letters*

Received date: 6-12-2016
Revised date: 18-1-2017
Accepted date: 9-3-2017

Please cite this article as: Chao Niu, Adila Tuerxuntayi, Gen Li, Madina Kabas, Chang-Zhi Dong, Haji Akber Aisa, Design, synthesis and bioactivity of chalcones and its analogues, Chinese Chemical Letters <http://dx.doi.org/10.1016/j.cclet.2017.03.018>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Original article

Design, synthesis and bioactivity of chalcones and its analogues

Chao Niu ^{a, b}, Adila Tuerxuntayi ^{a, b}, Gen Li ^{a, b}, Madina Kabas ^{a, b}, Chang-Zhi Dong ^{c *}, Haji Akber Aisa ^{a, b}

^a The Key Laboratory of Plant Resources and Chemistry of Arid Zone, Chinese Academy of Sciences, Urumqi 830011, China

^b State Key Laboratory Basis of Xinjiang Indigenous Medicinal Plants Resource Utilization, Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Urumqi 830011, China

^c Université Paris Diderot, Sorbonne Paris Cité, ITODYS, UMR 7086 CNRS, 15 rue J-A de Baïf, 75205 Paris Cedex 13, France

ARTICLE INFO

Article history:

Received 7 December 2016

Received in revised form 19 January 2017


Accepted 24 February 2017

Available online

* Corresponding author.

E-mail address: haji@ms.xjb.ac.cn

Graphical Abstract



Twenty-one chalcones and nine analogues were synthesized and evaluated for their activity on tyrosinase in cell-free system. Several compounds were more potent than the positive control 8-MOP and **13a** was further biologically investigated in B16 cells.

ABSTRACT

The *Vernohia anthelmintica* L.'s extract is one of the most popular Uygur medicines used for vitiligo. It is believed that the chalcone compounds of the plant play an important role in the treatment since they may activate tyrosinase and improve melanin production. In this study, twenty-one chalcones and nine analogues were synthesized in view of three different components of chalcone (A, B ring and α, β -unsaturated carbonyl). After biological evaluation of their activity on tyrosinase in cell-free systems, the result showed that most compounds (except polyhydroxy chalcones) possess activator effect on the tyrosinase, especially for **13a-15a**, **20a** and **1b**, which bearing a comparable activity to the positive control 8-MOP. SAR of these tyrosinase activator was summed up for the first time as well. Finally, compound **13a** was found to increase melanin contents and tyrosinase activity 1.75 and 1.3 fold, respectively, compared with that of untreated murine B16 cells at the concentration of 40 $\mu\text{g/mL}$.

Keywords:

Vitiligo

Activator of tyrosinase

Chalcone

B16 cells

SAR

1. Introduction

Vitiligo is an acquired pigmentary disorder of unknown etiology that is clinically characterized by the development of white macules related to the selective loss of melanocytes [1,2]. It was believed that the disease was mainly resulted from destruction of the melanocyte and obstruction of the melanin synthesis [3]. Tyrosinase is the rate-limiting enzyme in melanin biosynthesis and catalyze the reaction of hydroxylation and oxidation in the formation of melanin [4-8].

The fruits extract of *Vernohia anthelmintica* L. (Fig. 1) is one of the most popular Uygur medicines used for vitiligo and initially recorded in "Yao Yong Zong Ku" around 300 years ago [9-12]. Some important flavonoids are isolated from the plant [13-16] and it is suggested that these compounds play an important role in this treatments, since they may activate tyrosinase and improve the melanin production [17,18].

Unfortunately, few flavonoids as activator of tyrosinase have been reported [19-22]. Our group have been dedicated on the drug development of the vitiligo for many years [23-26]. And some chalcone derivatives with potential activating effect on tyrosinase and melanin synthesis in B16 cells were discovered as well [27-29]. Based on above research, twenty-one chalcones and nine analogues were prepared in view of three different parts of chalcone (A, B ring and α, β -unsaturated carbonyl). After that, the activity of them on tyrosinase were studied and the SAR was summarized as well.

2. Results and discussion

2.1 Chemistry

All the compounds were characterized by ^1H NMR, ^{13}C NMR, IR and HRMS (ESI). Firstly, nine mono-, di-, tri- and tetra-hydroxychalcones (**1a-9a**) were synthesized to study the impact of the hydroxyl for the activity on tyrosinase. The synthetic route was described in Scheme 1 (take Butein as example) [30]; Second, with the aim of investigating the significance of different substituents on phenyl ring for the effect on tyrosinase, compounds **10a-21a** substituted in different positions of A ring and *para*-position of B ring were prepared as well (Scheme 2); After that, five chalcone analogues (**1b-2b** and **1c-3c** in Fig. 2) with other aromatic A or B rings were synthesized respectively under the same condition as depicted in Scheme 2. At last, modification on the chain was explored by preparing four chain-prolonged chalcone analogues (**1d-4d** in Fig. 2) as represented in Fig. 2. Additionally, **1d** and **4d** were identified as novel compounds.

As shown in Fig. 3, the crystals of the compounds **13a** and **2c** used for X-ray diffraction analysis were obtained by slow evaporation of acetone-ethanol (1:3) mixed solution at room temperature (**13a**: CCDC No. 1451159; **2c**: CCDC No. 1451160).

2.2 Activity on tyrosinase

The biological activity of polyhydroxy chalcones against tyrosinase was evaluated (Table 1). All the compounds inhibit the tyrosinase. Generally, the higher inhibitory activity can be observed with more hydroxyl in chalcone. For **2a** and **3a**, **5a** and **6a**, the result showed that the most important factor for their efficacy was the location of the hydroxyl on benzene ring, with a significant preference to a 4-substituted B ring rather than a substituted A ring. Moreover, a 2,4-substituted resorcinol with more hydroxyl on ring A improved their activity, such as compounds **7a** and **9a**.

It was not hard to find that hydroxyl in chalcone skeleton seriously abolished the activator effect on tyrosinase according to the result above. Therefore, some other groups were introduced to the chalcone to improve the activity. As shown in Table 2, chalcones substituted with -X (**14a**, **15a**) and -N(CH₃)₂ (**13a**) were more potent than ones with -H, -OH, -CH₃ and -OCH₃, suggesting that the electron-withdrawing group (EWG) may be favorable to enhance the activity. In the view of best activity of compound **13a**, further modification was performed on this active molecule. Neither changing the location of the -OCH₃ on A ring nor replacement of -OCH₃ with -NO₂, -NH₂ or -NHAc enhanced the activator effect, which emphasizes the importance of the *para*-position of the substituted group on A ring and the -N(CH₃)₂ on B ring.

With few exceptions, when A ring was replaced with naphthalene or pyridine ring, similar effect was found with compound **1b** and **2b**, proving that the benzene for the A ring was not necessary for this effect. However, the activity dramatically decreased once other aromatic rings were introduced to B ring (compounds **1c-3c**), which means that the benzene for B ring was essential for maintaining the activity (Table 3). For the linker group between A and B ring, the α , β -unsaturated carbonyl was prolonged to give compound **1d-2d**, based on the active compounds synthesized above. Unfortunately, in Table 3, the extended distance between the two groups failed to retain the biological activity.

2.3 Activity on tyrosinase and melanin synthesis in B16 cells

The viability of **13a** on B16 melanoma cells was examined using the MTT assay. The cells were treated with various concentrations of **13a** (6.25-200 μ g/mL). As shown in Fig. 4, there was no significant difference between the control and treated group at concentrations of 6.25-200 μ g/mL. **13a** showed very small cytotoxic effects on B16 cells at concentrations of 200 μ g/mL.

The effect of **13a** on tyrosinase in cells was measured by L-DOPA oxidation (Fig. 5). Compared with treatment with medium only (untreated condition), treatment with **13a** at 0-40 μ g/mL resulted in a dose-dependent increase in tyrosinase activity in B16 cells. In the melanin content assay, to exclude the possibility that a rise in melanin content may be induced by cell-proliferating effect of **13a**, the absorbance of the same number of cells across **13a** concentrations (0-40 μ g/mL) was measured as well. We found that melanin levels increased in a dose-dependent manner by **13a** treatment in B16 cells (Fig. 6). At 40 μ g/mL of **13a**, the melanin content only slightly increased, so 20 μ g/mL was chosen as an effective concentration of **13a** for further experiments.

3. Conclusion

This work showed that good activator effect can be obtained with small chalcone molecules and the SAR was summed up for the first time as follows. (1) The hydroxyl on either benzene of chalcone may cause an inhibitory activity, especially for the B ring. (2) The A ring of the chalcone can be substituted with other conjugate aromatic rings to retain the activator effect while the B ring cannot. It was speculated that the planar molecule was essential for the activity. (3) The linker should not be prolonged for maintaining the activity. In addition, **13a** increased both activity of the tyrosinase and the contents of the melanin in a dose-dependent manner in murine B16 cells.

4. Experimental

4.1 Chemistry

Reagents and solvents were purchased from Sigma, Sodipro or VMR, and used without further purification. Dimethylsulfoxide (DMSO), mushroom tyrosinase, L-3, 4-dihydroxyphenylalanine (L-DOPA), 3,4-dihydroxyphenylalanine and 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) were purchased from Sigma (St. Louis, MO, USA).

4.2 General method for preparation of chalcone and analogues (**1a-21a**, **1b-2b**, **1c-3c**, **1d-4d**)

The corresponding aldehyde (1.0 equiv) and ketone (1.0 equiv) were dissolved in ethanol at 0 °C and 10% NaOH (1.0 equiv.) solution was slowly added. After that, the mixture was allowed to warm up to room temperature and stirred for 48 h. The resulting mixture was evaporated to dryness and the residue was purified by chromatography on silica gel eluted with petroleum ether-ethyl acetate to afford the final compound. The characterization data of the synthesized compounds are in the Supporting information.

4.3 Biological methods

Preparation of **13a**: Compound **13a** was obtained and then dissolved in DMSO. A stock solution of **13a** (5 mg/mL) was prepared in DMSO for further applications.

Cell culture: The murine B16 melanoma cell line was obtained from the CAS (Chinese Academy of Sciences, China). B16 cells were grown in DMEM medium (Gibco, Life Technologies, USA) supplemented with 10% heat-inactivated fetal bovine serum (Gibco), 100 U/mL penicillin and 100 µg/mL streptomycin (Hyclone, USA) in a humidified atmosphere with 5% CO₂ at 37 °C.

Cell viability assay: Cell viability was determined using the MTT assay. B16 cells were plated in 96-well dishes at a density of 5×10^3 cells per well. After 24 h, different concentrations of **13a** were added and the cells were incubated for 48 h. Then, 10 µL of MTT (5 mg/mL in PBS) solution was added into each well and the cells were incubated at 37 °C for another 4 h. Following medium removal, 150 µL of DMSO was added to each well and plates were gently shaken for 10 min. Optical absorbance was determined at 570 nm with a Spectra Max M5 (Molecular Devices, USA). Absorbance of cells without treatment was regarded as 100% cell survival. Each treatment was performed in quintuplicate and each experiment was repeated three times.

4.3.1 Activator effect of tyrosinase in cell-free assay

The activities on tyrosinase of synthesized compounds were performed according to the modified method [31], with 8-MOP [32-35] and Kojic acid [36-38] as positive control at the Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences. Potassium phosphate buffer (0.06 mL, 50 mmol/L) at pH 6.5, 0.04 mL tyrosinase (250 U/mL) and 2 µL of the test compounds (0.5-300 µmol/L), dissolved in DMSO were inserted into 96-well plates. After 5 min incubation at 25-30 °C, 0.1 mL of L-tyrosine (2 mmol/L) was added and incubated for additional 30 min. After that, the optical density of the systems at 490 nm was measured on ELASA and the rate of activation (RA) was calculated according the formula: $RA = [(C-D)-(A-B)]/(A-B) \times 100$, The A was optical density of the system at 490 nm with only tyrosinase; B was the one with neither compounds nor tyrosinase; C was the one with both compounds and tyrosinase; And the D was the one with only compounds. Finally, the activity of the compounds was expressed as the compounds concentration that gave a 50% activator effect (when RA=50%) in the enzyme activity (EC₅₀).

4.3.2 Tyrosinase activity and melanin content assay in B16 cells

Tyrosinase activity was estimated by measuring the rate of L-DOPA oxidation as previously reported. B16 cells were seeded in a 12-well plate at a density of 2×10^5 cells per well and allowed to attach for 24 h. Then, cells were treated with **13a** for 48 h, washed with ice-cold PBS twice, trypsinized with 0.25% trypsin (Hyclone) and collected in an Ep tube. After being centrifuged at 3,000 rpm for 5 min the cells were washed once with PBS, and then 200 µL of Tris-0.1% Triton X-100 (pH 6.8) were added to each tube. All tubes were incubated at -20 °C for 30 min, and then the lysates were centrifuged at 12,000 rpm for 15 min to obtain the supernatant for the tyrosinase activity assay. Protein concentrations were determined by the Bradford method with bovine serum albumin (BSA) as a standard. 100 µL of supernatant containing 10 µg total protein was added to each well in a 96-well plate and this was mixed with 100 µL of 0.1% L-DOPA in PBS (pH 6.8). After incubation at 37 °C for 1 h, the dopachrome was monitored by measuring the absorbance at 475 nm. The total melanin in the cell pellet was dissolved in 100 µL of 1 mol/L NaOH/10% DMSO for 1 h at 80 °C and solubilized melanin was measured at 470 nm.

Acknowledgment

This work was supported by the Funds for the Xinjiang Key Research and Development Program (No. 2016B03038-3); Personalized Medicines-Molecular Signature-based Drug Discovery and Development, Strategic Priority Research Program of the Chinese Academy of Sciences (No. XDA12050301); West Light Foundation of the Chinese Academy of Science (No. XBBS201403).

Appendix A. Supplementary data

Supplementary data (experimental procedures, spectroscopic characterizations) associated with this article can be found.

References

- [1] A. Alikhan, L. M. Felsten, M. Daly, V. Petronic-Rosic, Vitiligo: A comprehensive overview: Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up, *J. Am. Acad. Dermatol.* 65 (2011) 473-491.
- [2] M. Sandoval-Cruz, M. Garcia-Carrasco, R. Sanchez-Porras, et al., Vitiligo: A comprehensive overview: Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up, *Autoimmun. Rev.* 10 (2011) 762-765.
- [3] Namazi, M. R. Neurogenic dysregulation, oxidative stress, autoimmunity, and melanocytorrhage in vitiligo: Can they be interconnected? *Pigm. Cell Res.* 20 (2007) 360-363.
- [4] Y. Ye, J. H. Chu, H. Wang, et al., Involvement of p38 MAPK signaling pathway in the anti-melanogenic effect of San-bai-tang, a Chinese herbal formula, in B16 cells, *J. Ethnopharmacol.* 132 (2010) 533-535.
- [5] J. R. Whitaker, Polyphenol oxidase, in: Wong, D.W.S. (Ed.), *Food Enzymes, Structure and Mechanism*. Chapman & Hall, New York, 1995. pp 271-307.
- [6] T. C. Lei, Tyrosinase gene family and skin melanin biosynthesis, *Foreign Medsci-Sec Dermatol.* 24 (1998) 81-87.
- [7] M. M. Garcia-Molina, J. L. Muñoz-Muñoz, F. Garcia-Molina, P. A. García-Ruiz, F. Garcia-Canovas, Action of Tyrosinase on *ortho*-substituted phenols: Possible influence on browning and melanogenesis. *J. Agric. Food Chem.* 60 (2012) 6447-6455.
- [8] W. T. Ismaya, H. J. Rozeboom, A. Weijn, et al., Crystal structure of *Agaricus bisporus* mushroom tyrosinase: Identity of the tetramer subunits and interaction with tropolone, *Biochem.* 50 (2011) 5477-5486.
- [9] L. Yao, Q. Li, J. Shang, The effect of extract of different *Vernonia anthelmintica* L. on melanin synthesis and activity of tyrosinase in B16 cells, *J. Xinjiang Med. U.* 33 (2010) 1191-1193.
- [10] L. Sun, J. Shang, H. J. Li, L. Wu, The research on the anti-tumor chemical composition of *Vernonia anthelmintica* L. *J. Mod. Chinese Med.* 8 (2006) 10-12.
- [11] J. Zhou, J. Shang, F. F. Ping, G. R. Zhao, Alcohol extract from *Vernonia anthelmintica* (L.) willd seed enhances melanin synthesis through activation of the p38 MAPK signaling pathway in B16F10 cells and primary melanocytes, *J. Ethnopharmacol.* 143 (2012) 639-647.
- [12] A. Turak, Y. Q. Liu, H. A. Aisa, Elemnolide dimers from seeds of *Vernonia anthelmintica*, *Fitoterapia*, 104 (2015) 23-30.
- [13] J. F. Wu, S. Musadillin, S. C. Feng, F. H. Kong, R. S. Xu, Studies on chemical constituent of *Vernonia anthelmintica* Willd., *Acta Chimica Sinica*, 49 (1991) 1018-1022.
- [14] G. Tian, U. Zhang, T. Zhang, F. Yang, Y. Ito, Separation of flavonoids from the seeds of *Vernonia anthelmintica* Willd by high-speed counter-current chromatography, *J. Chromatogr. A*. 1049 (2004) 219-222.
- [15] R. N. Yadava, B. Bhargava, Phytochemical constituents from *Vernonia anthelmintica* Willd., *Int. J. Chem. Sci.* 8 (2010) 2470-2482.
- [16] L. M. Cai, S. X. Huo, J. Lin, P. P. Wu, K. Abudoukeremu, Chemical constituent of *Vernonia anthelmintica* (L.) Willd., *Chin. Tradit. Patent Med.* 34 (2012) 2159-2161.
- [17] J. Shang, J. G. Xu, L. H. Yu, L. Sun, H. J. Li, *CN 1778294A*, 2006 [Chem. Abstr. 2006, 145, 152560].
- [18] M. Yan, S. X. Huo, L. Gao, X. M. Peng, *CN 102526153A*, 2012 [Chem. Abstr. 2012, 157, 241762].
- [19] A. R. Nixha, M. Arslan, Y. Atalay, et al. Synthesis and theoretical calculations of carbazole substituted chalcone urea derivatives and studies their polyphenol oxidase enzyme activity, *J. Enzyme Inhib. Med. Chem.* 28 (2013) 808-815.
- [20] F. Sonmez, S. Sevmizler, A. Atahan, et al., Evaluation of new chalcone derivatives as polyphenol oxidase inhibitors, *Bioorg. Med. Chem. Lett.* 21 (2011) 7479-7482.
- [21] C. Dubois, R. Haudecoeur, M. Orio, et al., Versatile effects of aurone structure on mushroom tyrosinase activity, *ChemBioChem.* 13 (2012) 559-565.
- [22] R. Haudecoeur, A. Gouron, C. Dubois, et al., Investigation of binding-site homology between mushroom and bacterial tyrosinases by using aurones as effectors, *ChemBioChem.* 15 (2014) 1325-1333.
- [23] A. Tuerxuntayi, Y. Q. Liu, A. Tulake, et al., Kaliziri extract upregulates tyrosinase, TRP-1, TRP-2 and MITF expression in murine B16 melanoma cells, *BMC Complementary and Alternative Medicine.* 14 (2014) 166.
- [24] H. R. Li, M. Kabas, L. Z. Xie, H. A. Aisa, Effect of Chlorogenic Acid on Melanogenesis of B16 Melanoma Cells, *Molecules (Basel, Switzerland)*, 19 (2014) 12940-12948.
- [25] C. Niu, G. X. Pang, G. Li, et al., Synthesis and biological evaluation of furocoumarin derivatives on melanin synthesis in murine B16 cells for the treatment of vitiligo, *Bioorg. Med. Chem.* 24 (2016) 5960-5968.
- [26] Q. Ren, X. Y. Lu, J. X. Han, H. A. Aisa, T. Yuan, Triterpenoids and phenolics from the fruiting bodies of *Inonotus hispidus* and their activations of melanogenesis and tyrosinase, *Chin. Chem. Lett.* (2016), <http://dx.doi.org/10.1016/j.cclet.2016.12.010>.
- [27] C. Niu, G. Li, M. Kabas, H. A. Aisa, Synthesis and activity on tyrosinase of novel chalcone derivatives, *Chem. J. Chin. U.* 35 (2014) 1204-1211.
- [28] C. Niu, G. Li, A. Tuerxuntayi, H. A. Aisa, Synthesis and Bioactivity of New Chalcone Derivatives as Potential Tyrosinase Activator Based on the Click Chemistry, *Chin. J. Chem.* 33 (2015) 486-494.
- [29] C. Niu, L. Yin, L. F. Nie, et al., Synthesis and bioactivity of novel isoxazole chalcone derivatives on tyrosinase and melanin synthesis in murine B16 cells for the treatment of vitiligo, *Bioorg. Med. Chem.* 24 (2016) 5440-5448.
- [30] K. Damodar, J. K. Kimb, J. G. Jun, Synthesis and pharmacological properties of naturally occurring prenylated and pyranochalcones as potent anti-inflammatory agents, *Chin. Chem. Lett.* 27 (2016) 698-702.
- [31] S. Khatib, O. Nerya, R. Musa, et al., Chalcones as potent tyrosinase inhibitors: The importance of a 2,4-substituted resorcinol moiety, *Bioorg. Med. Chem.* 13 (2005) 433-441.
- [32] E. Pearl, M. D. Grimes, Psoralen photochemotherapy for vitiligo, *Clin. Dermatol.* 15 (1997) 921-926.
- [33] T. C. Lei, V. Victoria, K. Yasumoto, et al., Stimulation of melanoblast pigmentation by 8-methoxypsoralen: The involvement of microphthalmia-associated transcription factor, the protein kinase a signal pathway, and proteasome-mediated degradation, *J. Invest. Dermatol.* 119 (2002) 1341-1349.
- [34] M. Sensi, M. Catani, G. Castellano, et al., Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional axl receptor kinase, *J. Invest. Dermatol.* 131 (2011) 2448-2457.
- [35] E. Roh, C. Y. Yun, J. Y. Yun, et al., cAMP-binding site of PKA as a molecular target of bisabolangelone against melanocyte-specific hyperpigmented disorder, *J. Invest. Dermatol.* 133 (2013) 1072-1079.
- [36] G. Mi, B. Pérez, A. Harto, R. D. Misa, A. Ledo, 8-MOP bath PUVA in the treatment of psoriasis: Clinical results in 42 patients, *J. Dermatol. Treat.* 7 (2009) 11-12.
- [37] C. Balakrishna, N. Payili, S. Yennam, P. U. Devi, M. Behera, Synthesis of new kojic acid based unnatural α -amino acid derivatives, *Bioorg. Med. Chem. Lett.* 25 (2015) 4753-4756.
- [38] J. Y. Tang, J. B. Liu, F. Y. Wu, Molecular docking studies and biological evaluation of 1,3,4-thiadiazole derivatives bearing Schiff base moieties as tyrosinase inhibitors, *Bioorg. Chem.* 69 (2016) 29-36.

$$\text{A} - \text{C}(=\text{O}) - (\text{CH}=\text{CH})_n - \text{B}$$

$n=1 \text{ or } 2$





Fig. 3. Chemical structures of the crystals in **2c** and **13a**




Fig. 4. The Cell viability of **13a** determined using the MTT assay with different concentrations in B16 cells.




Fig. 5. Effect of **11a-13a** on tyrosinase in B16 cells (expressed as the percentage of untreated control).






Fig. 6. Effect of **11a-13a** on melanin content in B16 cells (expressed as the percentage of untreated control).

Table 1. The inhibitory effect of polyhydroxy chalcones on tyrosinase**1a-9a**

Compound	R ₁	R ₂	R ₃	R ₄	R	Substrate	IC ₅₀ ^a (μmol/L)
1a	H	H	H	H	H	L-tyrosine	NE ^b
2a	H	H	H	OH	H	L-tyrosine	35.4±2.02
3a	H	OH	H	H	H	L-tyrosine	NI ^c
4a	H	H	OH	OH	H	L-tyrosine	25.1±1.57
5a	OH	OH	H	H	H	L-tyrosine	NI
6a	OH	OH	H	OH	H	L-tyrosine	31.0±0.91
7a	OH	OH	OH	OH	H	L-tyrosine	19.6±1.42
8a	H	OH	OH	OH	H	L-tyrosine	27.3±2.64
9a	OH	OH	OH	OH	OH	L-tyrosine	11.4±1.03
Kojic acid ^d	-	-	-	-	-		10.70

^a 50% inhibitory concentration, result were the means±SD from three independent experiment; ^b not effect; ^c NI means slightly inhibited and IC₅₀>200 μmol/L; ^d Kojic acid as positive control

Table 2. The activator effect of substituted chalcones on tyrosinase**10a-21a**

Compound	R ₅	R ₆	Substrate	EC ₅₀ ^a (μmol/L)
10a	4-OCH ₃	H	L-tyrosine	NA ^b
11a	4-OCH ₃	OH	L-tyrosine	NA
12a	4-OCH ₃	CH ₃	L-tyrosine	58.4±6.54
13a	4-OCH ₃	N(CH ₃) ₂	L-tyrosine	17.1±2.18
14a	4-OCH ₃	Cl	L-tyrosine	26.3±1.67
15a	4-OCH ₃	F	L-tyrosine	20.6±3.58
16a	4-OCH ₃	OCH ₃	L-tyrosine	126.0±8.21
17a	2-OCH ₃	N(CH ₃) ₂	L-tyrosine	NA
18a	3-OCH ₃	N(CH ₃) ₂	L-tyrosine	46.3±4.60
19a	4-NO ₂	N(CH ₃) ₂	L-tyrosine	NA
20a	4-NH ₂	N(CH ₃) ₂	L-tyrosine	35.5±0.87
21a	4-NHAc	N(CH ₃) ₂	L-tyrosine	NA
8-MOP ^c			L-tyrosine	14.6

^a 50% effective concentration, result were the means±SD from three independent experiment; ^b NA means slightly activated and EC₅₀>200 μmol/L; ^c 8-MOP as positive control

Table 3. The activator effect of chalcone analogues on tyrosinase

Compound	Substrate	EC ₅₀ ^a (μmol/L)
1b	L-tyrosine	25.8±1.73
2b	L-tyrosine	41.7±2.25
1c	L-tyrosine	NA ^b
2c	L-tyrosine	NA
3c	L-tyrosine	NA
1d	L-tyrosine	84.0±7.51
2d	L-tyrosine	73.6±5.36
3d	L-tyrosine	NA ^b
4d	L-tyrosine	NA
8-MOP ^c	L-tyrosine	14.6

^a 50% effective concentration, result were the means±SD from three independent experiment; ^b NA means slightly activated and EC₅₀>200 μmol/L; ^c 8-MOP as positive control